Soufflé Therapeutics

Therapeutic Devices · Watertown, MA · Founded 2021 · Privately Held (backing)

Developer of a targeted gene therapy intended to treat autoimmune diseases and cardiac diseases. Soufflé Therapeutics is based in Watertown, MA and was founded in 2021. It was valued at $345 million at its early-stage round in Oct 2025, the last priced event on record. It has raised $241 million across 1 recorded round; the latest was a $200 million Series A in Oct 2025.

PMV mark · valuation
$344.5M
Oct 2026
Priced at
its early-stage round
Oct 2025
Total raised
$240.6M
Last round
Early Stage VC (Series A)
Oct 2025
What is Soufflé Therapeutics worth?
$344.5MPrivateMarketView mark · Oct 2026

Valued at $344.5M at its early-stage round, Oct 2025. Nothing has traded since.

Free account
More of Soufflé Therapeutics with a free account
  • ·The complete investor list: 13 names
  • ·Watch Soufflé Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Soufflé Therapeutics funding history

1 rounds
DateRoundRaisedPost-money
Oct 2025Early Stage VC (Series A)$200.0M▮
Unlock post-money valuations

Membership and data by Private Market View

Soufflé Therapeutics valuation

Soufflé Therapeutics was valued at $345 million at its early-stage round in Oct 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Soufflé Therapeutics raised?

Soufflé Therapeutics has raised $241 million across 1 recorded round since 2025. The largest was a $200 million Series A in Oct 2025.

Comparable companies

Comparable therapeutic devices names by valuation on PrivateMarketView: Saluda Medical ($435 million), LightForce ($400 million) and Galvanize Therapeutics ($300 million).

How Soufflé Therapeutics's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Soufflé Therapeutics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about Soufflé Therapeutics

What is Soufflé Therapeutics worth?
Soufflé Therapeutics is valued at $344.5M as of Oct 2026. Valued at $344.5M at its early-stage round, Oct 2025. Nothing has traded since.
How much has Soufflé Therapeutics raised?
Soufflé Therapeutics has raised $240.6M in total funding across 1 recorded rounds.
When did Soufflé Therapeutics last raise?
Soufflé Therapeutics last raised in Oct 2025 (Early Stage VC (Series A)), raising $200.0M.